Receptor for advanced glycation end products involved in circulating endothelial cells release from human coronary endothelial cells induced by C-reactive protein

Document Type: Original Article


Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003 China


Objective(s): This study was designed to investigate the effect of receptor for advanced glycation end products (RAGE), S100A12 and C-reactive protein (CRP) on the release of circulating endothelial cells (CECs) from human coronary artery endothelial cells (HCAECs).
Materials and Methods: HCAECs were cultured in increasing concentration of CRP (0, 12.5, 25, 50μg/ml) or S100A12 protein (0, 4, 10, 25μg/ml) for 24 hr. CECs were measured by flow cytometry. Small interfering RNA (siRNA) was designed to decrease RAGE level. Fluorescence microscopy and real-time quantitative polymerase chain reaction were used to assess the efficiency of siRNA silencing RAGE. The release of CECs from HCAECs was further evaluated by flow cytometry.
Results: CRP caused a significant increase in the release of CECs from HCAECs. The number of CECs increased by about 2-fold in 25 μg/ml CRP-treated group compared to the control group (12.22% compared to 6.82%, P=0.032). But S100A12 failed to increase the release of CECs from HCAECs. Blockade of RAGE by siRNA significantly decreased the release of CECs induced by CRP (13.22% of CRP group compared to 8.77% of CRP+siRNA group, P=0.017).
Conclusion:RAGE is involved in the release of CECs induced by CRP, and the effect can be attenuated by silencing RAGE. RAGE may play an important role in endothelial dysfunction in cardiovascular disease. Inhibition of RAGE may be a therapeutic target for coronary artery lesions in Kawasaki disease.


1. Kitano N, Suzuki H, Takeuchi T, Suenaga T, Kakimoto N, Shibuta S, et al. Epidemiologic features and prognostic factors of coronary artery lesions associated with Kawasaki disease based on a 13-year cohort of consecutive cases identified by complete enumeration surveys in Wakayama, Japan. J Epidemiol 2014; 24:427-434.

2. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108:949-955.

3. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196:9-21.

4. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001; 21:905-910.

5. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111: 959-972.

6. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97:889-901.

7. Gimbrone MA Jr. Endothelial dysfunction, hemodynamic forces, and atherosclerosis. Thromb Haemost 1999; 82:722-726.

8. Dignat-George F, Sampol J. Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur J Haematol 2000; 65:215-220.

9. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93:2951-2958.

10. Fu S, Gong F, Xie C, Zhu W, Wang W, Shen H, et al. S100A12 on circulating endothelial cells surface in children with Kawasaki disease. Pediatr Res 2010; 68:165-168.

11. Gong F, Zhang Y, Xie C, Zhu W, Wang W, Fu S, et al. Expression of receptor for advanced glycation end products (RAGE) on the surface of circulating endothelial cells is upregulated in Kawasaki disease. Pediatr Res 2012; 71:720-724.

12. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006; 113:2135-2150.

13. Devaraj S, Kumaresan PR, Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem 2011; 57:1757-1761.

14. Yan SD, Bierhaus A, Nawroth PP, Stern DM. Endothelial precursor cells and CRP on the RAGE: activation or cell death? J Cardiovasc Pharmacol 2009; 53:349-351.

15. Zhong Y, Li SH, Liu SM, Szmitko PE, He XQ, Fedak PW, et al. C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 2006; 48:504-511.

16. Chen J, Huang L, Song M, Yu S, Gao P, Jing J. C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells. J Cardiovasc Pharmacol 2009; 53:359-367.

17. Chen J, Jin J, Song M, Dong H, Zhao G, Huang L. C-reactive protein down-regulates endothelial nitric oxide synthase expression and promotes apoptosis in endothelial progenitor cells through receptor                 for advanced glycation end-products. Gene 2012; 496:128-135.

18. Koyanagi H, Yanagawa H, Nakamura Y, Yashiro M. Serum C-reactive protein levels in patients with Kawasaki disease: from the results of nation-wide surveys of Kawasaki disease in Japan. Acta Paediatr 1997; 86:613-619.

19. Mitani Y, Sawada H, Hayakawa H, Aoki K, Ohashi H, Matsumura M, et al.  Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005; 111:38-43.

20. Moroz OV, Antson AA, Dodson EJ. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr 2002; 58:407-413.

21. Moroz OV, Burkitt W, Wittkowski H, He W, Ianoul A, Novitskaya V, et al. Both Ca2+ and Zn2+ are essential for S100A12 protein oligomerization and function. BMC Biochem 2009; 10:11.

22. Herbert M, Coppieters N, Lasham A, Cao H, Reid G. The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. BMC Res Notes 2011; 25:148.

23. Holmes K, Williams CM, Chapman EA, Cross MJ. Detection of siRNA induced mRNA silencing by RT-qPCR: considerations for experimental design. BMC Res Notes 2010; 3:53.

24. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106:1439-1441.

25. Hein TW, Singh U, Vasquez-Vivar J. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009; 206:61-68.

26. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269:9889-9897.

27. Coughlan MT, Thorburn DR, Penfold SA, Lasko-wski A, Harcourt BE, Sourris KC, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009; 20:742-752.

28. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43:562-571.